These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 21707493)

  • 1. Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.
    Loh KC; Baldwin D; Saba JD
    Anticancer Agents Med Chem; 2011 Nov; 11(9):782-93. PubMed ID: 21707493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.
    Kitatani K; Taniguchi M; Okazaki T
    Mol Cells; 2015 Jun; 38(6):482-95. PubMed ID: 25997737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.
    Ponnusamy S; Meyers-Needham M; Senkal CE; Saddoughi SA; Sentelle D; Selvam SP; Salas A; Ogretmen B
    Future Oncol; 2010 Oct; 6(10):1603-24. PubMed ID: 21062159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective role of sphingolipid rheostat in excitotoxic retinal ganglion cell death.
    Nakamura N; Honjo M; Yamagishi R; Kurano M; Yatomi Y; Watanabe S; Aihara M
    Exp Eye Res; 2021 Jul; 208():108623. PubMed ID: 34022173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Sphingolipid Rheostat in Gliomas.
    Zaibaq F; Dowdy T; Larion M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of sphingosine kinase in hematological malignancies and other cancers.
    Pitson SM; Powell JA; Bonder CS
    Anticancer Agents Med Chem; 2011 Nov; 11(9):799-809. PubMed ID: 21707491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
    Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
    Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer treatment strategies targeting sphingolipid metabolism.
    Oskouian B; Saba JD
    Adv Exp Med Biol; 2010; 688():185-205. PubMed ID: 20919655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration.
    Jęśko H; Stępień A; Lukiw WJ; Strosznajder RP
    Mol Neurobiol; 2019 May; 56(5):3501-3521. PubMed ID: 30140974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
    Kilbey A; Terry A; Wotton S; Borland G; Zhang Q; Mackay N; McDonald A; Bell M; Wakelam MJ; Cameron ER; Neil JC
    J Cell Biochem; 2017 Jun; 118(6):1432-1441. PubMed ID: 27869314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-configuration of sphingolipid metabolism by oncogenic transformation.
    Don AS; Lim XY; Couttas TA
    Biomolecules; 2014 Mar; 4(1):315-53. PubMed ID: 24970218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic applications of bioactive sphingolipids in hematological malignancies.
    Ekiz HA; Baran Y
    Int J Cancer; 2010 Oct; 127(7):1497-506. PubMed ID: 20503271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of autophagy by sphingolipids.
    Bedia C; Levade T; Codogno P
    Anticancer Agents Med Chem; 2011 Nov; 11(9):844-53. PubMed ID: 21707487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)].
    Loughran TP; Wang HG
    Anticancer Agents Med Chem; 2011 Nov; 11(9):780-1. PubMed ID: 22023044
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of bioactive sphingolipids in physiology and pathology.
    Gomez-Larrauri A; Presa N; Dominguez-Herrera A; Ouro A; Trueba M; Gomez-Muñoz A
    Essays Biochem; 2020 Sep; 64(3):579-589. PubMed ID: 32579188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingolipids in cancer.
    Furuya H; Shimizu Y; Kawamori T
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):567-76. PubMed ID: 22005951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets.
    Kawabori M; Kacimi R; Karliner JS; Yenari MA
    World J Cardiol; 2013 Apr; 5(4):75-86. PubMed ID: 23675553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine 1-Phosphate Signaling and Metabolism in Chemoprevention and Chemoresistance in Colon Cancer.
    Grbčić P; Sedić M
    Molecules; 2020 May; 25(10):. PubMed ID: 32456134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.
    Sukocheva OA; Neganova ME; Aleksandrova Y; Burcher JT; Chugunova E; Fan R; Tse E; Sethi G; Bishayee A; Liu J
    Cell Commun Signal; 2024 May; 22(1):251. PubMed ID: 38698424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of ceramide in cancer treatment.
    Moro K; Nagahashi M; Gabriel E; Takabe K; Wakai T
    Breast Cancer; 2019 Jul; 26(4):407-415. PubMed ID: 30963461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.